Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on...

Related Keywords

Boston ,Massachusetts ,United States ,New York ,San Diego ,California ,American ,Kimberly Blackwell ,Mark Lackner ,Program Updates ,Exchange Commission ,Nasdaq ,Zentalis Pharmaceuticals Inc ,Translational Sciences ,Genentech ,Globenewswire Inc ,Pfizer ,Genentech Oncology Early Stage Biomarker Group ,Blackwell ,Development Expenses ,Linkedin ,Pharmaceuticals Inc ,American Association For Cancer Research ,Zentalis Pharmaceuticals ,Translational Officer ,Chief Scientific Officer ,Chief Executive Officer ,Chief Translational Officer ,New Drug Application ,Cancer Research ,Special Conference ,Staining Is Frequent ,Prior Platinum Treatment ,High Grade Serous Ovarian ,Ovarian Cancer ,Biomarker Strategy ,Senior Vice President ,Oncology Early Stage Biomarker ,Marketable Securities Position ,Administrative Expenses ,Securities Litigation Reform Act ,Consolidated Statements ,Markets ,